Moderna

Moderna has become the newest member of the UK’s pharmaceutical industry body, the Association of the British Pharmaceutical Industry (ABPI), building on the long-term commitment by the American-based company to expand its footprint and investment in the UK.  Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reportedly has ‘high ambitions’ for rapid […]

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive Officer and co-founder of BioNTech, […]

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with mRNA-4157/V940, which is being developed by Moderna and Merck (MSD), […]

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck on PCVs since 2016, and […]

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty infringes Moderna’s patents for its […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s Covid-19 booster vaccine that targets two coronavirus variants.  Moderna’s ‘Spikevax’ booster dose targets the original coronavirus strain as well as the Omicron variant. Known as a bivalent vaccine, Spikevax was approved following data that show it triggers a strong immune […]

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported for 14 of the top players, with five […]

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Moderna’s Spikevax, an mRNA vaccine for prevention of Covid-19 in individuals 18 years of age and older.  Official comments   “Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalisation […]

IAVI and Moderna have announced that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, DC.  The trial  The Phase I trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting […]

Moderna has dosed the first participant in a Phase II study of the company’s Omicron-specific booster candidate (mRNA-1273.529). Additionally, Moderna announced the publication of neutralising antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine.   The mRNA-1273.529 trial  This extension of an earlier study will evaluate the immunogenicity, safety, and reactogenicity of […]